هـــه‌مــوو كـتێبه‌كانى بابـه‌تـى ئـینگلـیزى (Sunrise) لـه‌ پـۆلـى (یـه‌كـه‌م)ى بـنه‌ڕه‌تیه‌وه‌ بۆ پـۆلـى (دوازده‌)ى ئـامـاده‌یـى: (كـتێبـى چالاكـى، كـتێبى خـوێـندكار، كـتێبى مامـۆسـتا) كـلیـك...

SunRISe-5 (NCT06211764) was presented as a featured clinical trial in progress during the 2024 American Urological Association Annual Meeting. The phase 3 study is investigating TAR-200, an intravesical gemcitabine treatment, in patients with non-muscle invasive bladder cancer who have previously received Bacillus Calmette-Guérin (BCG).

SunRISe-5 (NCT06211764) is a randomized, open-label, multicenter phase III trial that is evaluating the safety and efficacy of TAR-200 compared with investigator’s choice of intravesical chemotherapy in patients with papillary-only, high-risk NMIBC that recurs within the first year of BCG treatment who either refuse or are ineligible for ...

2025年1月20日 · SunRISe-5 (NCT06211764) is a phase 3, randomized, open-label, multicenter study that will evaluate the efficacy and safety of TAR-200 vs investigator’s choice of intravesical chemotherapy (mitomycin C or gemcitabine) in patients with recurrent, papillary-only high-risk non-muscle-invasive bladder cancer (HR-NMIBC) who received Bacillus ...

SunRISe-5 (NCT06211764) is a randomized, open-label, multicenter phase 3 study that evaluates the safety and efficacy of TAR-200 compared with investigator’s choice of intravesical chemotherapy in patients with papillary-only HR NMIBC that recurs within the first year of BCG treatment who either refuse or are ineligible for radical cystectomy ...

SunRISe-5: A Phase 3, Randomized, Open-Label Study of TAR-200 Compared With Intravesical Chemotherapy After Bacillus Calmette–Guérin in Recurrent High-Risk Non–Muscle-Invasive Bladder Cancer Sima Porten 1, Sumeet Bhanvadia 2, Saltanat Najmi 3, Hussein Sweiti 4, John Maffeo 5,Katharine Stromberg 5, Benjamin Pradere 6 1

SunRISe-5 (NCT06211764) is a randomized, open-label, multicenter phase 3 study that evaluates the safety and efficacy of TAR-200 compared with intravesical chemotherapy in patients with papillary-only HR NMIBC that recurs

SunRISe-5 A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)

2024年6月18日 · Sima Porten provides an overview of the SunRISe-5 trial, a Phase III study evaluating TAR-200, a novel drug delivery system for patients with recurrent high-risk non-muscle invasive bladder cancer (NMIBC) who have not responded to BCG treatment.

2024年5月6日 · About the Phase 3 SunRISe-5 Study of TAR-200 | TargetedOnc.com | May 06, 2024